Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ABC Transporters - 40 Years onMechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

ABC Transporters - 40 Years on: Mechanistic and Pharmacological Insights into Modulation of ABC... [ATP-binding cassette (ABC) drug transporters have both physiological and pharmacological importance in humans. They not only protect the cells from xenobiotics, but also alter the pharmacokinetics and toxicity of drugs that are substrates for these transporters. P-glycoprotein (P-gp) was the first human ABC transporter to be discovered, almost four decades ago. Drug transport using the energy harvested by ATP hydrolysis is a hallmark of ABC drug transporters and has been extensively studied to determine its mechanism of substrate specificity and transport activity. Structural information from a number of human P-gp homologs highlights the existence of multiple drug-binding sites that can interact with a diverse set of chemically or structurally unrelated compounds. Tyrosine kinase inhibitors (TKIs) comprise a class of drugs that interact with ABC transporters with high affinity and are reported to be transport substrates of several ABC transporters. A number of preclinical and clinical studies have shown that ABC transporters influence the disposition of several TKIs that include altered pharmacokinetics and safety profiles and have a role in the development of resistance to this class of therapeutics. Structural details regarding the TKIs’ effect on ABC transporters have not been thoroughly explored. This review summarizes preclinical and clinical observations on the interaction of TKIs with ABC drug transporters. In addition, we provide structural information on the interaction of two TKIs, nilotinib and imatinib, at the drug-binding regions within P-gp and ABCG2. This information could help to generate a novel scaffold that would be an ideal TKI with potent inhibition of kinases, but minimal interactions with ABC drug transporters.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

ABC Transporters - 40 Years onMechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

Editors: George, Anthony M.
Shukla, Suneet; Patel, Atish; Ambudkar, Suresh V.
ABC Transporters - 40 Years on — Dec 17, 2015
Download PDF
45 pages

Loading next page...
 
/lp/springer-journals/abc-transporters-40-years-on-mechanistic-and-pharmacological-insights-0OTAlPKB0X

References (255)

Publisher
Springer International Publishing
Copyright
© Springer International Publishing Switzerland 2016
ISBN
978-3-319-23475-5
Pages
227 –272
DOI
10.1007/978-3-319-23476-2_10
Publisher site
See Chapter on Publisher Site

Abstract

[ATP-binding cassette (ABC) drug transporters have both physiological and pharmacological importance in humans. They not only protect the cells from xenobiotics, but also alter the pharmacokinetics and toxicity of drugs that are substrates for these transporters. P-glycoprotein (P-gp) was the first human ABC transporter to be discovered, almost four decades ago. Drug transport using the energy harvested by ATP hydrolysis is a hallmark of ABC drug transporters and has been extensively studied to determine its mechanism of substrate specificity and transport activity. Structural information from a number of human P-gp homologs highlights the existence of multiple drug-binding sites that can interact with a diverse set of chemically or structurally unrelated compounds. Tyrosine kinase inhibitors (TKIs) comprise a class of drugs that interact with ABC transporters with high affinity and are reported to be transport substrates of several ABC transporters. A number of preclinical and clinical studies have shown that ABC transporters influence the disposition of several TKIs that include altered pharmacokinetics and safety profiles and have a role in the development of resistance to this class of therapeutics. Structural details regarding the TKIs’ effect on ABC transporters have not been thoroughly explored. This review summarizes preclinical and clinical observations on the interaction of TKIs with ABC drug transporters. In addition, we provide structural information on the interaction of two TKIs, nilotinib and imatinib, at the drug-binding regions within P-gp and ABCG2. This information could help to generate a novel scaffold that would be an ideal TKI with potent inhibition of kinases, but minimal interactions with ABC drug transporters.]

Published: Dec 17, 2015

Keywords: ABC transporters; ABCG2; Multidrug resistance; P-glycoprotein; Pharmacokinetics; Targeted therapeutics; Tyrosine kinase inhibitors

There are no references for this article.